Gabapentin Tablet
Product Images NDC 71610-737

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-737). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 800 mg (71610 0737 30)

Gabapentin USP 800 mg oral tablet label showing a 30 tablet package. The label includes storage instructions, manufacturing details by SciGen Pharmaceuticals Inc in Hauppauge, NY, and repackaging by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. It also displays the NDC number 71610-0737-30, barcodes, batch, and GTIN information.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an 8-week period for placebo and Gabapentin at 3600 mg/day. The X-axis represents weeks with baseline and weekly intervals, and the Y-axis shows mean pain scores ranging from 0 to 10. The graph highlights a 4-week dose titration period followed by a 4-week fixed dose period, showing a decreasing trend in pain scores for Gabapentin compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over 7 weeks for placebo and Gabapentin at 1800 mg/day and 2400 mg/day. The graph includes a 3-week dose titration period and a 4-week fixed dose period. Pain scores decrease for both Gabapentin doses compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It shows data from two studies comparing placebo (PBO) with Gabapentin (GBP) at doses of 1800, 2400, and 3600 mg. The percentage of responders is displayed for each group, with Gabapentin groups showing higher response rates than placebo. Statistical significance markers indicate p-values less than 0.01 and 0.001.*

FDA Label Image

Image-04 (Image 04)

Mathematical formula for creatinine clearance (CLCr) calculation showing variables including age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. The formula is part of clinical pharmacology or dosing information typically seen in drug labeling.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing a cyclohexane ring attached to an amino methyl group and an acetic acid moiety.*

FDA Label Image

Image-09 (Image 09)

A scatter plot comparing percentage difference on the vertical axis to daily dose in mg on the horizontal axis for three studies labeled as STUDY a, STUDY b, and STUDY c. Data points are shown at daily doses of approximately 600, 900, 1200, and 1800 mg, with each study represented by distinct square markers. The chart visually compares outcomes across different daily gabapentin doses in the studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.